Sales of Humira increased 18 percent to $3.1 billlion. Humira is the world’s top selling prescription drug, approved to treat more than a dozen conditions including psoriasis and rheumatoid arthritis.
The North Chicago-based company’s results were weighed down by a $1.9 billion in one-time costs, including a breakup fee from its abandoned merger with Shire PLC. That left it with earnings of $1.02 billion, or 63 cents per share, for the first quarter.
Adjusted earnings were 94 cents per share on revenue of 5.04 billion, beating analyst estimates of 85 cents per share on revenue of $5.01 billion.
The company expects full-year earnings of $4.10-$4.30, up from $4.05-$4.25.